Stock BRM BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bristol-Myers Squibb Company BOERSE MUENCHEN

Equities

BRM

US1101221083

Real-time BOERSE MUENCHEN
Other stock markets
 12:13:51 27/06/2024 am IST 		5-day change 1st Jan Change
39.82 EUR +1.08% Intraday chart for Bristol-Myers Squibb Company +3.66% -15.27%
06:28pm Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
05:27pm Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-15.27% 8.55TCr -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.54% 81TCr
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.25% 65TCr
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.19% 35TCr
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+21.32% 34TCr
B-
ABBVIE INC. Stock AbbVie Inc.
+11.01% 30TCr
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 25TCr
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.09% 23TCr
A+
NOVARTIS AG Stock Novartis AG
+13.03% 22TCr
B-
AMGEN INC. Stock Amgen Inc.
+8.95% 17TCr
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BRM Stock
  5. Ratings Bristol-Myers Squibb Company